👉Three important conclusions are agreed upon regarding this clinical entity:
– Prognosis of occult primary breast cancer is the same or slightly better than women with classic stage IIA disease (T0, N1, M0)
– An exhaustive workup for the non-breast primary is usually not fruitful
– Treatment of the breast in some manner decreases the risk of local failure over time.
👉Modified radical mastectomy has been the traditional surgical treatment for many years.
👉Previously, the primary breast cancer was found in the mastectomy specimen 40% to 80% of the time, but with the advent of much better mammography and ultrasound along with breast MRI, this rate is much lower now.
👉However, what was true then and still holds today is that no treatment to the breast itself results in an unacceptably high local recurrence rate.
👉An alternative to a modified radical mastectomy is complete ALND followed by whole-breast irradiation.
👉Axillary dissection provides local control while also fine tuning staging.
👉Theoretically the whole-breast radiation should control any subclinical disease in the breast not detected on imaging.
👉Primary radiation to the breast, axilla, and supraclavicular area without any surgery of the breast or axilla results in higher local and regional recurrence compared to surgery and radiation combined.
👉Axillary node dissection and whole-breast irradiation has been found to have equivalent survival as a modified radical mastectomy.
👉A recent meta-analysis of seven studies and more than 240 patients with occult primary breast cancers (0.3% to 0.8% of all breast cancers). found 39% were treated with ALND and radiation while 47% had modified radical mastectomy and 15% had ALND alone.
👉With a mean follow-up of 5 years, the study found no difference in local regional recurrence (12.7 vs 9.8 %), distant metastasis (7.2 vs 12.7 %), or mortality (9.5 vs 17.9 %) between ALND and radiation vs modified radical mastectomy (all p>0.16).
👉ALND with radiation was superior to ALND alone in terms of local regional recurrence (12.7 vs 34.3 %, p < 0.01) and trended towards improved survival but this was not statistically significant (P=0.09).
- Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M. The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. Eur J Cancer. 2011;47:2099-2106. PMID: 21658935. http://www.ncbi.nlm.nih.gov/pubmed/21658935
- Dockery MB, Gray HK, Pierce EH. Surgical significance of isolated axillary adenopathy. Ann Surg. 1957;145:104-107. http://www.ncbi.nlm.nih.gov/pubmed/13395289
- Macedo FI, Eid JJ, Flynn J, Jacobs MJ, Mittal VK. Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol. 2016;23:1838-1844. https://www.ncbi.nlm.nih.gov/pubmed/26832884
- Rueth NM, Black DM, Limmer AR, et al. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015;22:90-95. [epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/25249256
- Walker GV, Smith GL, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116:4000-4006. PMID: 20564117. http://www.ncbi.nlm.nih.gov/pubmed/20564117
- Woo SM, Son BH, Lee JW, et al. Survival outcomes of different treatment methods for the ipsilateral breast of occult breast cancer patients with axillary lymph node metastasis: a single center experience. J Breast Cancer. 2013;16:410-416. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893343/
👉Rodrigo Arrangoiz MS, MD, FACS miembro de Sociedad Quirúrgica y cirujano oncólogo de mama.
Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO
My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida.
I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016.
Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida.
Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.
View all posts by Rodrigo Arrangoiz MS, MD, FACS, FSSO